Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pathophysiological impacts of tafamidis on cardiac transthyretin amyloidosis (PICTA)
jRCT1041200007Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tafamidis in transthyretin amyloidosis (ATTR) and amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Boehringer Ingelheim. Primary endpoint: Change in myocardial amyloid deposition area. Started Oct 2020; status: active, not recruiting.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloidosis (ATTR)amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on jRCT1041200007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041200007.